Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Uterine fibroid embolization reduces fibroid-related urinary symptoms

Uterine fibroid embolization—an interventional radiology treatment for the noncancerous yet very common growths that develop in the muscular wall of the uterus—improves a number of women's lower urinary tract problems that are specifically caused by those fibroids, confirm researchers at the Society of Interventional Radiology's 36th Annual Scientific Meeting in Chicago, Ill.

30 Mar 2011

URMC research confirms possible use of mifepristone for painful fibroids

Research continues to show that the controversial abortion drug mifepristone might have another use, as a therapeutic option besides hysterectomy for women who suffer from severe symptoms associated with uterine fibroids.

8 Mar 2011

Philips introduces new innovative and cost-effective solutions for radiology at ECR 2011

At the European Congress of Radiology 2011, Royal Philips Electronics is ushering in a new era in radiology science with Imaging 2.0, a concept fueled by integration of technology, clinician and patient.

5 Mar 2011

Uterine fibroid treatments greatly improve quality of life in women

Women who received one of three treatments for uterine fibroids at Brigham and Women's Hospital in Boston said their symptoms diminished and their quality of life significantly increased, according to a new study published in the May issue of Radiology.

1 Mar 2011

U.S. District Court rules in favor of Hologic in breast brachytherapy patent infringement lawsuit

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced that the United States Court of Appeals for the Federal Circuit has ruled in favor of Hologic, by reversing the previous decisions reached by the United States District Court for the Northern District of California, in favor of SenoRx, Inc.

From Hologic, Inc. 28 Feb 2011

FDA approves Hologic's 3-D digital mammography system to diagnose breast cancer

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostic products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, today announced the Company received approval from the U.S. Food and Drug Administration for its Selenia Dimensions digital breast tomosynthesis system.

From Hologic, Inc. 14 Feb 2011

Hologic receives FDA approval for hydroxyprogesterone caproate injection

Hologic, a leading developer, manufacturer and supplier of premium diagnostics products, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today the U.S. Food and Drug Administration has approved Hologic's pharmaceutical named Makena, formerly known as Gestiva.

From Hologic, Inc. 4 Feb 2011

Miracle baby after radical new procedure for uterine fibroids

Amy Cordle is the first woman in Australia to become a mother after undergoing a radical new procedure. On Australia Day, the 31-year-old Albert Park woman’s little “miracle” arrived when daughter Neroli was born.

3 Feb 2011

Uterine health is more relevant for fetus to achieve normal birth weight, full gestation

For women seeking pregnancy by assisted reproductive technologies, such as in-vitro fertilization, a new study shows that the health of the uterus is more relevant than egg quality for a newborn to achieve normal birth weight and full gestation.

2 Feb 2011

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Boston Scientific Corporation today announced that the U.S. Food and Drug Administration has approved its Renegade HI-FLO Fathom Pre-Loaded System for selective access and delivery of diagnostic, embolic and therapeutic materials into the peripheral vasculature.

1 Feb 2011

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

During an investor meeting held today in New York, NY, Watson Pharmaceuticals, Inc. provided an update on its Global businesses, including a detailed overview of its commercial operations and pipeline developments within its Global Generics and Global Brands businesses, and an update of achievements within its Global Operations. In conjunction with the meeting, the Company provided its preliminary 2011 financial and long term growth forecasts.

21 Jan 2011

Hologic announces acquisition of Interlace Medical

Hologic, Inc., a leading developer, manufacturer and supplier of premium diagnostics, medical imaging systems and surgical products dedicated to serving the healthcare needs of women, announced today it has acquired Interlace Medical, Inc. (Interlace), the developer and manufacturer of the MyoSure hysteroscopic tissue removal system (MyoSure). Interlace's operations will be integrated within Hologic's GYN Surgical Products division.

From Hologic, Inc. 7 Jan 2011

FDA approves Watson's novel oral contraceptive

Watson Pharmaceuticals today announced the U.S. Food and Drug Administration (FDA) approval of a novel oral contraceptive product – the first and only low dose oral contraceptive to combine 0.8 mg norethindrone and 0.025 mg ethinyl estradiol in chewable form, with four 75 mg ferrous fumarate (iron) placebo tablets. Taken orally, once daily, the product is proven effective in lowering the risk of pregnancy.

22 Dec 2010

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Women suffering from uterine fibroids, a debilitating condition that affects more than seven million women in the U.S., may soon have reason for hope. Halt Medical, a biomedical company based in the San Francisco Bay Area, is developing a minimally invasive procedure for treating the condition. The company recently presented their findings from studies in Latin America at the NIH Global Fibroid Congress.

21 Dec 2010

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Repros Therapeutics Inc. today announced it has commenced preparation for dosing the 3 mg cohort in the Company's low dose study of Proellex® following a safety review of data from women that have completed 8 weeks of treatment at a 1 mg dose. No signals of liver toxicity were detected to date in the 1 mg group. Unexpectedly, low levels of drug activity were detected in this first cohort. The Company plans to commence dosing of the second group, 3 mg Proellex, next week.

17 Dec 2010

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

Watson Pharmaceuticals, Inc. and Gedeon Richter Plc today announced that Watson's subsidiary, Watson Laboratories, Inc. has entered into an exclusive licensing agreement with PregLem, S.A., ("Preglem") the wholly owned subsidiary of Richter, to develop and market Esmya™ (ulipristal acetate) in the U.S. and Canada.

16 Dec 2010

New robotic arm device for early to mid-stage osteoarthritis

A robotic arm device developed to assist orthopedic surgeons with performing partial knee replacement surgery for early to mid-stage osteoarthritis is now available at NewYork-Presbyterian Hospital/Columbia University Medical Center. The technology was approved by the FDA in 2005, and to date nearly 5,000 cases have been performed in the U.S.

3 Dec 2010

Elbit Imaging closes transaction with Enter

Elbit Imaging Ltd. announced today that, further to its announcement dated September 13, 2010, it has successfully closed the transaction with Enter Holdings 1 Ltd. and Enter's controlling shareholders.

25 Nov 2010

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Neurocrine Biosciences, Inc. today announced its financial results for the quarter ended September 30, 2010.

29 Oct 2010

Halt Medical's Tulip RFVTA probe granted Canadian approval for treatment of uterine fibroids

Halt Medical, Inc. announced today that it has been approved to market the Tulip™ Radiofrequency Volumetric Thermal Ablation (RFVTA) probe in Canada. "The license we just received from Health Canada brings us an important step closer to our goal of making our uterine sparing procedure available to the millions of women in North America who suffer with uterine fibroids", said Russ DeLonzor, President and COO of Halt Medical.

19 Oct 2010

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Uterine fibroid embolization reduces fibroid-related urinary symptoms

URMC research confirms possible use of mifepristone for painful fibroids

Philips introduces new innovative and cost-effective solutions for radiology at ECR 2011

Uterine fibroid treatments greatly improve quality of life in women

U.S. District Court rules in favor of Hologic in breast brachytherapy patent infringement lawsuit

FDA approves Hologic's 3-D digital mammography system to diagnose breast cancer

Hologic receives FDA approval for hydroxyprogesterone caproate injection

Miracle baby after radical new procedure for uterine fibroids

Uterine health is more relevant for fetus to achieve normal birth weight, full gestation

FDA approves Boston Scientific's Renegade HI-FLO Fathom Pre-Loaded System

Watson predicts $4.2 billion in revenues from Global Generics and Global Brand businesses

Hologic announces acquisition of Interlace Medical

FDA approves Watson's novel oral contraceptive

Halt Medical presents results of Halt Fibroid Study at NIH Global Fibroid Congress

Repros prepares for dosing 3 mg cohort in low dose Proellex study in uterine fibroids and endometriosis

Watson, PregLem enter licensing agreement to develop, market Esmya in the U.S. and Canada

New robotic arm device for early to mid-stage osteoarthritis

Elbit Imaging closes transaction with Enter

Neurocrine third quarter revenue increases from $0.7 million to $14.4 million

Halt Medical's Tulip RFVTA probe granted Canadian approval for treatment of uterine fibroids

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Uterine Fibroids News and Research

Latest Uterine Fibroids News and Research

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

From Puberty to Menopause: Clue’s CEO, Audrey Tsang on the Power of Femtech

Newsletters you may be interested in